Teniposide

Topoisomerase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Teniposide is an ofm drug in the Topoisomerase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1992. Its mechanism of action is classified as Topoisomerase Inhibitors. DrugCentral lists 5 molecular targets, including ABCB1, TOP2A and ABCG2. Recorded indications include Acute lymphoid leukemia.

• Approval status: ofm (first approved 1992 by the FDA).
• Drug class: Topoisomerase Inhibitor.
• Mechanism of action: Topoisomerase Inhibitors.
• Molecular targets: ABCB1, TOP2A, ABCG2 and ABCC6 (5 listed in DrugCentral).
• Indications: Acute lymphoid leukemia.
• ATC code: L01CB02 (Podophyllotoxin derivatives).
• Molecular formula: C32H32O13S; molecular weight 656.66 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Acute lymphoid leukemia

Off-label uses (2)

• Follicular non-Hodgkin's lymphoma
• Neuroblastoma

Contraindications (9)

• Bacterial infectious disease
• Bone marrow depression
• Breastfeeding (mother)
• Complete trisomy 21 syndrome
• Disease of liver
• Kidney disease
• Pregnancy, function
• Stupor
• Viral disease

Mechanism & targets

• Mechanism of action (MoA): Topoisomerase Inhibitors
• Established pharmacologic class: Topoisomerase Inhibitor

Molecular targets (5)

Target	Gene	Action	Activity
Multidrug resistance protein 1	ABCB1	unknown	—
DNA topoisomerase 2-alpha	TOP2A	inhibitor	—
ATP-binding cassette sub-family G member 2	ABCG2	unknown	—
Multidrug resistance-associated protein 6	ABCC6	unknown	—
Canalicular multispecific organic anion transporter 2	ABCC3	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1992-07-14	FDA	—	HQ SPECLT PHARMA	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01CB02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS › Podophyllotoxin derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Ototoxicity	440.6
Deafness	223.3
Product use in unapproved indication	98.1

Chemical structure

• Molecular formula: C₃₂H₃₂O₁₃S
• Molecular weight: 656.66 g/mol
• CAS number: —
• InChIKey: NRUKOCRGYNPUPR-QBPJDGROSA-N
• PubChem CID: 452548

COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)C2=CC=CS2)C2=CC3=C(OCO3)C=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Teniposide used for?

DrugCentral lists the following indications for Teniposide: Acute lymphoid leukemia.

How does Teniposide work?

Teniposide is classified as Topoisomerase Inhibitors; its molecular targets in DrugCentral include ABCB1, TOP2A (inhibitor), ABCG2 and ABCC6.

When was Teniposide first approved?

Teniposide was first approved by the FDA in 1992.

What drug class does Teniposide belong to?

Teniposide is in the Topoisomerase Inhibitor class.

What is the chemical formula of Teniposide?

Teniposide has the molecular formula C32H32O13S and a molecular weight of 656.66 g/mol.

Sources

• DrugCentral drug card 2590 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL452231 — compound record and bioactivity
• PubChem CID 452548 — chemical identifiers
• DrugBank DB00444 — drug record
• FDA UNII 957E6438QA — substance identity
• DailyMed: FDA labels for Teniposide — current prescribing information (label search)
• UniProt P08183 (ABCB1) — target protein
• UniProt P11388 (TOP2A) — target protein
• UniProt Q9UNQ0 (ABCG2) — target protein
• UniProt O95255 (ABCC6) — target protein
• UniProt O15438 (ABCC3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.